MAXHEALTH - Max Healthcare Institute Limited Share Price

Healthcare Services

₹1099.80+32.40(+3.04%)

Market Closed as of Apr 28, 2025, 15:30 IST

What does Max Healthcare Institute Limited do?

Hospital•Healthcare•Mid Cap

Max Healthcare Institute is a prominent hospital company based in Gurugram, India, operating under the stock ticker MAXHEALTH.

With a market capitalization of Rs. 95,341.8 Crores, the company offers a wide range of medical and healthcare services across various specialties. These include advanced cardiac care, orthopaedics, oncology, renal sciences, neurosciences, minimal access metabolic and bariatric surgery, obstetrics, gynaecology, paediatrics, nephrology, general surgery, and specialized transplants such as liver, heart, kidney, lung, and bone marrow.

In addition to its hospital services, Max Healthcare Institute provides innovative health and wellness solutions through platforms like Max@Home, which offers at-home healthcare, and MaxLab, which delivers diagnostic services beyond its network of hospitals via third-party laboratory management.

The company boasts a strong financial performance, reporting a trailing 12-month revenue of Rs. 6,695.7 Crores and a profit of Rs. 1,008.4 Crores over the past four quarters. Max Healthcare has experienced significant growth, with a revenue increase of 70.4% in the past three years.

For its investors, Max Healthcare distributes dividends, currently yielding 0.25% annually, with a reported Rs. 2.5 dividend per share in the last 12 months. However, itÃ¢â‚¬â„¢s worth noting that the company has diluted its shareholders by 0.3% over the past three years. Established in 2001, Max Healthcare continues to expand its network of healthcare facilities, including hospitals and medical centers, contributing to its reputation as a leading healthcare provider in India.

Industry Group:Healthcare Services

Employees:19,500

Website:www.maxhealthcare.in

Summary of Latest Earnings Report from Max Healthcare Institute

Summary of Max Healthcare Institute's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.

Earnings Outlook

Last updated: Feb 25

Management Outlook:
Max Healthcare's management expressed strong confidence in continued growth, driven by strategic expansions, operational efficiency, and successful integration of acquisitions. Key highlights include:

Growth Momentum: Achieved 30% YoY growth in revenue, EBITDA, and occupied bed days. New hospitals (Dwarka, Lucknow, Nagpur) and acquisitions (Jaypee Noida) are contributing positively, with Dwarka reaching EBITDA breakeven in 6 months.
Expansion Strategy: Focus on asset-light, "built-to-suit" models (Thane, Mohali) to maximize ROCE. Capacity expansions (500 beds in Thane by 2028, 400 beds in Mohali) and brownfield projects (Nanavati, Max Smart, Gurgaon) are on track, adding ~1,300 beds over 12 months.
Operational Efficiency: Existing units saw 7% YoY ARPOB growth and improved EBITDA margins (28.6%). Annualized EBITDA per bed rose to Rs.73 lakhs, with new units expected to enhance profitability as capacity scales.
Financial Discipline: Net debt at Rs.1,608 crores (0.65x EBITDA), maintaining a conservative cap of 2.5x. Strong free cash flow (Rs.303 crores in Q3) supports growth and dividends.
Market Optimism: Anticipated price revisions in institutional segments (CGHS/PSUs) and resilience in international patient revenue (+28% YoY despite geopolitical challenges).
Therapy Mix & Innovation: Focus on expanding high-margin services (oncology, robotics) and digital initiatives (Max@Home, Max Lab) to diversify revenue.

Key Forward-Looking Points:

Commissioning of 268 beds at Nanavati (Q1 FY26) and brownfield expansions to drive near-term occupancy.
Expected resolution of delays (e.g., Vikrant Saket's forest approvals).
Target to sustain industry-leading ROCE through asset-light models and operational leverage.

Management remains bullish on inorganic opportunities and market share gains, underpinned by robust demand and execution capabilities.

Q&A Session

Last updated: Feb 25

1. Question: Why did existing units' revenue remain flat quarter-on-quarter despite Q3 typically being a weak season?
Answer: Q3's flat revenue was due to higher-than-expected occupancy during Diwali (unlike typical seasonal drops). Festive impacts were mitigated by timing (Diwali at month-end) and operational efficiency. Year-on-year growth, not sequential trends, better reflects performance.

2. Question: Are price hikes expected for insurance schemes?
Answer: No insurance-specific price hikes are anticipated. Institutional rate revisions (e.g., CGHS) are expected soon. Insurance rate adjustments occur organically during contract renewals, maintaining ~6% annual medical inflation.

3. Question: How is Lucknow's market evolving, and what drives future profitability?
Answer: Lucknow's strong demand justifies adding 140 beds (64 in Jan/Feb 2025). A new radiation bunker (July 2025) will boost oncology revenue. Market competition remains unchanged (Apollo, Medanta), with growth driven by capacity expansion and clinical programs.

4. Question: Why did Nagpur's EBITDA decline quarter-on-quarter?
Answer: Seasonality (vector-borne diseases in Q2 caused temporary spikes) and Q3's 79% occupancy (still healthy). Year-on-year growth (22% revenue, 50% EBITDA) reflects strong performance. Future expansion (127 beds post-clearance) targets higher ROCE.

5. Question: How will upcoming projects be funded, and what is the debt tolerance?
Answer: Net debt-to-EBITDA is capped at 2.5x (currently 0.65x post-Jaypee). Asset-light models (Thane, Mohali) minimize capital outlay. Annual free cash flow (~Rs.1,200 crore) and conservative leverage support expansion.

6. Question: What is the impact of institutional bed share (~30%) on margins?
Answer: Institutional beds optimize idle capacity, boosting fixed-cost absorption. Margins benefit from operational leverage, especially in brownfields. Preference remains for higher-margin segments, but institutional revenue aids EBITDA growth during expansions.

7. Question: How will asset-light hospitals (e.g., Thane) affect margins?
Answer: Asset-light models prioritize ROCE (100%+ post-stabilization) over EBITDA margins. Rent costs (post-EBITDA) reduce margins by ~5-6% vs. owned assets, but lower capital risk and developer-funded construction enhance returns.

8. Question: What are the risks from IRDAI's senior citizen insurance cap?
Answer: Minimal impact. Insurers' permitted 10% annual premium hikes exceed hospitals' negotiated ~6% rate increases. Policies retain affordability, sustaining patient volume. No direct rate negotiations with hospitals are anticipated.

9. Question: How will Mumbai's expansion impact beds and margins?
Answer: Phase 1 adds 268 beds (no net reduction). Phase 2 replaces 160 outdated ward beds with premium beds, improving ARPOB. Margins rise via operating leverage and right-sized capacity, aligning with demand for single/deluxe rooms.

10. Question: Why did PHF profitability decline?
Answer: PHFs upstreamed higher fees to Max Healthcare (Rs.25 crore annual impact). Balaji/DDF donations to other trusts reduced reported EBITDA but align with tax-exempt objectives. No dividend risk; surplus cash supports group projects.

Pros

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Size: It is among the top 200 market size companies of india.

Technicals: Bullish SharesGuru indicator.

Smart Money: Smart money has been increasing their position in the stock.

Profitability: Recent profitability of 15% is a good sign.

Balance Sheet: Strong Balance Sheet.

Growth: Awesome revenue growth! Revenue grew 24.7% over last year and 70.4% in last three years on TTM basis.

Cons

Momentum: Stock is suffering a negative price momentum. Stock is down -4.9% in last 30 days.

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Rank

Balance Sheet

Momentum

Technicals

Smart Money

Insider Trading

Sector Comparison: MAXHEALTH vs Healthcare Services

Comprehensive comparison against sector averages

Comparative Metrics

MAXHEALTH metrics compared to Healthcare

Category	MAXHEALTH	Healthcare
PE	102.90	37.86
PS	15.50	6.83
Growth	24.7 %	-1.3 %

Performance Comparison

MAXHEALTH vs Healthcare (2021 - 2025)

Key Insights

1. MAXHEALTH is among the Top 3 Hospital companies by market cap.
2. The company holds a market share of 10.6% in Hospital.
3. In last one year, the company has had an above average growth that other Hospital companies.

Share Holdings

Understand Max Healthcare Institute ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Major Shareholders

Share Holding Details

As of 2025-03-31

Shareholder Name	Holding %
Abhay Soi	23.73%
Government of Singapore	5.69%
New World Fund Inc	5.33%
Smallcap World Fund, Inc	3.55%
HDFC Mutual Fund	1.76%
SBI Mutual Fund	1.74%
Monetary Authority of Singapore	1.49%
Motilal Oswal Mutual Fund	1.36%
Canara Robeco Mutual Fund	1.28%
Vanguard Total International Stock Index Fund	1.08%
Kotak Mutual Fund	1.08%
Kotak Funds - India Midcap Fund	1.06%
Axis Mutual Fund	1.02%
Unclaimed or Suspense or Escrow Account	0.13%
Aditya Soi	0.01%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Income Statement for Max Healthcare Institute

Standalone figures (in Rs. Crores) / View Consolidated Data

QuarterlyAnnual

Description	(%) Q/Q	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023	Sep-2023
Revenue From Operations	1.6%	697	686	621	610	591	597
Other Income	-31.6%	92	134	43	138	43	48
Total Income	-3.8%	789	820	664	748	633	645
Purchases of stock-in-trade	3%	140	136	120	112	104	108
Employee Expense	0%	123	123	119	113	113	116
Finance costs	221.2%	23	7.85	7.64	15	10	13
Depreciation and Amortization	3.2%	33	32	30	32	30	28
Other expenses	-1%	200	202	187	184	175	170
Total Expenses	3.4%	518	501	461	457	430	435
Profit Before exceptional items and Tax	-14.5%	272	318	203	291	203	210
Exceptional items before tax	-	-73.63	0	0	0	0	0
Total profit before tax	-37.9%	198	318	203	291	203	210
Current tax	8%	55	51	44	40	42	40
Deferred tax	-87.1%	5.38	35	4.57	9.16	3.14	8.97
Total tax	-31.4%	60	87	49	49	45	49
Total profit (loss) for period	-40.4%	138	231	154	242	158	161
Other comp. income net of taxes	26.6%	-0.05	-0.43	-0.93	0.05	0.31	-2.34
Total Comprehensive Income	-40.4%	138	231	153	242	158	159
Earnings Per Share, Basic	-69.6%	1.42	2.38	1.59	2.49	1.63	1.66
Earnings Per Share, Diluted	-70.1%	1.41	2.37	1.58	2.48	1.62	1.66

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Revenue From Operations	22.9%	2,341	1,905	1,729	1,031
Other Income	88.8%	271	144	125	107
Total Income	27.5%	2,613	2,049	1,854	1,137
Purchases of stock-in-trade	21.5%	430	354	446	237
Employee Expense	20.5%	448	372	364	265
Finance costs	0%	52	52	44	112
Depreciation and Amortization	3.6%	117	113	99	91
Other expenses	16.9%	700	599	501	359
Total Expenses	17.6%	1,748	1,486	1,451	1,073
Profit Before exceptional items and Tax	53.7%	865	563	403	64
Exceptional items before tax	-	0	0	0	-210.67
Total profit before tax	53.7%	865	563	403	-146.46
Current tax	31.5%	147	112	65	0
Deferred tax	112.3%	31	-243.1	6.92	18
Total tax	233.9%	178	-131.17	72	18
Total profit (loss) for period	-1%	687	694	331	-164.45
Other comp. income net of taxes	-910%	-2.03	0.7	0.87	-0.34
Total Comprehensive Income	-1.4%	685	695	332	-164.79
Earnings Per Share, Basic	-1.5%	7.07	7.16	3.42	-1.91
Earnings Per Share, Diluted	-1.6%	7.05	7.15	3.42	-1.91

Consolidated figures (in Rs. Crores) / View Standalone Data

QuarterlyAnnual

Description	(%) Q/Q	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023	Sep-2023
Revenue From Operations	9.4%	1,868	1,707	1,543	1,423	1,335	1,363
Other Income	-20%	33	41	35	45	46	45
Total Income	8.8%	1,902	1,748	1,578	1,468	1,381	1,409
Purchases of stock-in-trade	10.6%	397	359	330	297	271	278
Employee Expense	7.4%	305	284	270	242	231	236
Finance costs	54.5%	52	34	24	21	11	8.53
Depreciation and Amortization	16.9%	98	84	77	70	61	58
Other expenses	7.9%	673	624	559	504	451	460
Total Expenses	10.5%	1,519	1,375	1,256	1,132	1,021	1,042
Profit Before exceptional items and Tax	2.1%	382	374	321	336	360	366
Exceptional items before tax	-	-73.63	0	0	0	0	0
Total profit before tax	-17.4%	309	374	321	336	360	366
Current tax	-1.1%	91	92	81	74	75	71
Deferred tax	-2745.5%	-20.91	0.23	3.69	11	-4.74	19
Total tax	-24.2%	70	92	85	84	70	90
Total profit (loss) for period	-15.3%	239	282	236	252	289	277
Other comp. income net of taxes	58.9%	-0.36	-2.31	-1.75	-0.85	-0.66	-4.37
Total Comprehensive Income	-15.1%	238	280	235	251	289	272
Earnings Per Share, Basic	-23.2%	2.46	2.9	2.43	2.588	2.98	2.85
Earnings Per Share, Diluted	-23.4%	2.44	2.88	2.42	2.575	2.97	2.84

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Revenue From Operations	18.5%	5,406	4,563	3,931	2,505
Other Income	28.3%	178	139	127	115
Total Income	18.8%	5,584	4,702	4,059	2,619
Purchases of stock-in-trade	19.4%	1,119	937	930	581
Employee Expense	15.5%	934	809	760	589
Finance costs	-28.9%	60	84	101	179
Depreciation and Amortization	5.6%	245	232	221	174
Other expenses	17%	1,861	1,591	1,306	918
Total Expenses	16%	4,219	3,638	3,311	2,454
Profit Before exceptional items and Tax	28.3%	1,365	1,064	748	165
Exceptional items before tax	-	0	0	-9.03	-233.7
Total profit before tax	28.3%	1,365	1,064	739	-68.65
Current tax	32.4%	271	205	116	2.43
Deferred tax	114.3%	36	-244.57	18	43
Total tax	852.6%	308	-39.79	134	46
Total profit (loss) for period	-4.2%	1,058	1,104	605	-137.55
Other comp. income net of taxes	-403.4%	-6.45	-0.48	2.65	0.51
Total Comprehensive Income	-4.7%	1,051	1,103	608	-137.04
Earnings Per Share, Basic	-4.7%	10.886	11.376	6.25	-1.59
Earnings Per Share, Diluted	-5%	10.842	11.356	6.24	-1.59

Investor Care
Dividend Yield	0.26%
Dividend/Share (TTM)	2.5
Shares Dilution (1Y)	0.03%
Diluted EPS (TTM)	10.31

Financial Health
Current Ratio	1.26
Debt/Equity	0.2
Debt/Cashflow	0.86

Cash Flow for Max Healthcare Institute

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022
Finance costs	-2.1%	47	48	0
Change in inventories	104%	1.25	-5.28	-3.17
Depreciation	3.6%	117	113	99
Unrealised forex losses/gains	-50%	-0.14	0.24	0
Dividend income	-	91	0	0
Adjustments for interest income	35%	163	121	0
Share-based payments	28.6%	37	29	30
Net Cashflows from Operations	-2.9%	762	785	527
Interest paid	-	0	0	-39.99
Interest received	-	0	0	-94.43
Income taxes paid (refund)	70.1%	149	88	48
Net Cashflows From Operating Activities	-11.9%	613	696	425
Cashflows used in obtaining control of subsidiaries	1995.2%	441	22	185
Proceeds from sales of PPE	84.7%	4.38	2.83	1.54
Purchase of property, plant and equipment	286.6%	461	120	367
Purchase of other long-term assets	-	0	0	161
Cash receipts from repayment of advances and loans made to other parties	5.8%	110	104	20
Dividends received	-	91	0	0
Interest received	-100.8%	0	130	95
Other inflows (outflows) of cash	128%	242	-860.48	0
Net Cashflows From Investing Activities	4.4%	-805.64	-842.85	-733.03
Proceeds from issuing shares	-119.4%	0.94	1.31	3.66
Proceeds from exercise of stock options	-5.3%	0	0.05	0
Proceeds from borrowings	-96.3%	4.44	94	12
Repayments of borrowings	128%	115	51	44
Payments of lease liabilities	-102%	0	51	22
Dividends paid	-	97	0	0
Interest paid	-14.9%	41	48	25
Other inflows (outflows) of cash	-	12	0	0
Net Cashflows from Financing Activities	-345.1%	-245.91	-54.47	-75.33
Net change in cash and cash eq.	-117.7%	-438.46	-200.85	-383.79

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022
Finance costs	-47.1%	38	71	0
Change in inventories	130.9%	5.9	-14.87	-7.56
Depreciation	5.6%	245	232	221
Unrealised forex losses/gains	86.6%	0.91	0.33	0.34
Adjustments for interest income	58.3%	153	97	0
Share-based payments	48.5%	50	34	34
Net Cashflows from Operations	1.5%	1,391	1,370	840
Interest paid	-	0	0	-90.01
Interest received	-	0	0	-72.08
Income taxes paid (refund)	67.5%	269	161	109
Net Cashflows From Operating Activities	-7.2%	1,122	1,209	748
Cashflows used in obtaining control of subsidiaries	121254%	631	0.48	107
Proceeds from sales of PPE	82.9%	6.34	3.92	5.17
Purchase of property, plant and equipment	132.2%	779	336	561
Purchase of investment property	-	7.17	0	0
Purchase of other long-term assets	-	0	0	171
Cash receipts from repayment of advances and loans made to other parties	-102.9%	0	35	32
Interest received	78.8%	153	86	74
Other inflows (outflows) of cash	97%	-27.83	-976.06	0
Net Cashflows From Investing Activities	-8.3%	-1,285.45	-1,187.01	-771.77
Proceeds from issuing shares	-119.4%	0.94	1.31	3.66
Proceeds from exercise of stock options	-5.3%	0	0.05	0
Proceeds from borrowings	10460.1%	642	7.07	57
Repayments of borrowings	235.1%	564	169	250
Payments of lease liabilities	-	58	0	14
Dividends paid	-	97	0	0
Interest paid	165.7%	187	71	91
Net Cashflows from Financing Activities	8.6%	-263.74	-288.56	-294.17
Effect of exchange rate on cash eq.	-	-1.82	0	0
Net change in cash and cash eq.	-60.9%	-429.21	-266.39	-317.45

Balance Sheet for Max Healthcare Institute

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022	Mar-2022
Cash and cash equivalents	12.4%	808	719	1,310	13	45	214
Loans, current	60%	33	21	15	17	14	12
Total current financial assets	36.7%	1,356	992	1,648	1,400	871	666
Inventories	7.1%	31	29	28	30	25	25
Current tax assets	-	-	0	16	-	0.87	0
Total current assets	36%	1,396	1,027	1,701	1,436	903	698
Property, plant and equipment	6.6%	1,339	1,256	999	985	929	942
Capital work-in-progress	19.5%	154	129	72	57	30	14
Goodwill	0%	1,319	1,319	1,319	1,319	1,319	947
Non-current investments	1.4%	1,941	1,915	1,549	1,475	1,470	2,567
Loans, non-current	10.8%	741	669	388	438	437	633
Total non-current financial assets	3.5%	2,997	2,896	2,231	2,208	2,275	3,427
Total non-current assets	2.4%	8,232	8,042	7,045	6,984	7,038	6,804
Total assets	6.2%	9,629	9,069	8,746	8,420	7,941	7,502
Borrowings, non-current	14.1%	463	406	466	501	424	416
Total non-current financial liabilities	14.1%	463	406	466	501	424	416
Provisions, non-current	16.7%	29	25	24	20	19	20
Total non-current liabilities	11.4%	976	876	923	937	890	897
Borrowings, current	8.3%	40	37	27	32	29	33
Total current financial liabilities	39.9%	625	447	494	388	258	257
Provisions, current	15.4%	31	27	24	18	44	16
Total current liabilities	38.4%	708	512	568	441	328	296
Total liabilities	21.3%	1,684	1,388	1,491	1,378	1,218	1,193
Equity share capital	0%	972	972	972	971	970	970
Total equity	3.4%	7,945	7,681	7,255	7,042	6,723	6,309
Total equity and liabilities	6.2%	9,629	9,069	8,746	8,420	7,941	7,502

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022	Mar-2022
Cash and cash equivalents	-1.6%	964	980	1,582	43	194	309
Loans, current	-	0	0	0	0	2.16	2.58
Total current financial assets	16%	1,860	1,603	2,256	1,835	1,228	917
Inventories	16.5%	93	80	72	76	62	61
Current tax assets	-	-	3.92	-	16	22	0
Total current assets	16.1%	1,981	1,706	2,366	1,943	1,332	1,000
Property, plant and equipment	20.7%	3,919	3,246	2,069	2,019	1,939	1,954
Capital work-in-progress	32.2%	588	445	254	207	124	105
Investment property	0%	63	63	0	0	0	0
Goodwill	0%	2,951	2,952	2,455	2,455	2,455	2,455
Non-current investments	68.8%	2.89	2.12	0.51	0.51	0.51	0.51
Loans, non-current	70.8%	235	138	138	138	173	173
Total non-current financial assets	14.4%	534	467	447	448	556	557
Total non-current assets	8.3%	11,146	10,294	8,291	8,159	8,171	8,189
Total assets	9.4%	13,127	12,000	10,656	10,102	9,504	9,189
Borrowings, non-current	32.2%	1,570	1,188	588	604	668	629
Total non-current financial liabilities	26%	1,926	1,529	923	924	1,062	1,178
Provisions, non-current	20.3%	90	75	69	60	60	60
Total non-current liabilities	17.8%	2,760	2,343	1,676	1,647	1,775	2,149
Borrowings, current	80.7%	198	110	73	84	101	97
Total current financial liabilities	27.1%	1,360	1,070	977	913	672	650
Provisions, current	15%	70	61	61	48	74	42
Total current liabilities	25.6%	1,568	1,249	1,134	1,046	811	757
Total liabilities	20.5%	4,328	3,592	2,810	2,692	2,586	2,907
Equity share capital	0%	972	972	972	971	970	970
Total equity	4.7%	8,799	8,408	7,846	7,410	6,918	6,282
Total equity and liabilities	9.4%	13,127	12,000	10,656	10,102	9,504	9,189

Is Max Healthcare Institute Better than it's peers?

Detailed comparison of Max Healthcare Institute against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
APOLLOHOSP	Apollo Hospitals EnterprisesHospital	1.01 LCr	21.31 kCr	+6.39%	+8.65%	75.09	4.75	+15.13%	+64.06%
FORTIS	Fortis HealthcareHospital	50.97 kCr	7.62 kCr	+1.39%	+47.16%	61.83	6.69	+12.17%	+42.06%
NH	Narayana HrudayalayaHospital	36.75 kCr	5.48 kCr	+9.70%	+41.17%	46.87	6.71	+8.88%	+1.56%
MEDANTA	Global HealthHospital	32.26 kCr	3.65 kCr	-0.46%	-15.57%	63.6	8.83	+12.56%	+12.29%
KIMS	Krishna Institute of Medical SciencesHospital	26.86 kCr	2.9 kCr	+10.06%	+66.93%	70.7	9.25	+18.28%	+4.60%
SHALBY	ShalbyHospital	2.04 kCr	1.09 kCr	-2.59%	-33.45%	67.83	1.87	+19.89%	-62.94%

Valuation
Market Cap	1.07 LCr
Price/Earnings (Trailing)	106.02
Price/Sales (Trailing)	15.97
EV/EBITDA	59.43
Price/Free Cashflow	283.88
MarketCap/EBT	79.81

Fundamentals
Revenue (TTM)	6.7 kCr
Rev. Growth (Yr)	37.7%
Rev. Growth (Qtr)	8.77%
Earnings (TTM)	1.01 kCr
Earnings Growth (Yr)	-17.47%
Earnings Growth (Qtr)	-15.26%

Profitability
Operating Margin	21.11%
EBT Margin	20.01%
Return on Equity	11.46%
Return on Assets	7.68%
Free Cashflow Yield	0.35%

MAXHEALTH - Max Healthcare Institute Limited Share Price

What does Max Healthcare Institute Limited do?

Summary of Latest Earnings Report from Max Healthcare Institute

Sector Comparison: MAXHEALTH vs Healthcare Services

Comparative Metrics

Performance Comparison

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

Income Statement for Max Healthcare Institute

Investor Care

Financial Health

Cash Flow for Max Healthcare Institute

Balance Sheet for Max Healthcare Institute

Is Max Healthcare Institute Better than it's peers?

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)